EyePoint, Inc. continues to build on its proprietary sustained intraocular drug delivery platform, Durasert E™, aiming to transform retinal disease treatment with its lead candidate DURAVYU™, currently in pivotal Phase 3 trials for wet AMD and diabetic macular edema. Despite significant revenue growth and increasing R&D investment driving widening operating losses, the company maintains a strong liquidity position but signals a need for additional capital. Regulatory risks—including ongoing DOJ investigations—and competition from established anti-VEGF therapies remain critical headwinds as the company approaches key data readouts expected mid-2026 that will crucially influence its commercial outlook.